Insulet
Market Cap
€12.1b
Last Updated
2020/02/22 21:47 UTC
Data Sources
Company Financials +
Executive Summary
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with questionable track record.
Similar Companies
Share Price & News
How has Insulet's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GOV has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.5%
GOV
1.4%
DE Medical Equipment
-0.9%
DE Market
1 Year Return
156.8%
GOV
25.2%
DE Medical Equipment
12.8%
DE Market
Return vs Industry: GOV exceeded the German Medical Equipment industry which returned 25% over the past year.
Return vs Market: GOV exceeded the German Market which returned 13.7% over the past year.
Shareholder returns
| GOV | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.5% | 1.4% | -0.9% |
| 30 Day | 12.6% | -4.8% | -0.2% |
| 90 Day | 21.7% | 1.1% | 3.0% |
| 1 Year | 156.8%156.8% | 27.1%25.2% | 16.3%12.8% |
| 3 Year | 357.2%357.2% | 141.7%135.4% | 15.8%5.7% |
| 5 Year | 618.6%618.6% | 275.2%256.5% | 19.8%3.4% |
Price Volatility Vs. Market
How volatile is Insulet's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Insulet undervalued compared to its fair value and its price relative to the market?
767.84x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GOV (€196) is trading above our estimate of fair value (€93.7)
Significantly Below Fair Value: GOV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GOV is poor value based on its PE Ratio (782.8x) compared to the Medical Equipment industry average (42.1x).
PE vs Market: GOV is poor value based on its PE Ratio (782.8x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: GOV is poor value based on its PEG Ratio (18.7x)
Price to Book Ratio
PB vs Industry: GOV is overvalued based on its PB Ratio (88.8x) compared to the DE Medical Equipment industry average (5.9x).
Next Steps
Future Growth
How is Insulet forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
41.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GOV's forecast earnings growth (41.8% per year) is above the savings rate (-0.4%).
Earnings vs Market: GOV's earnings (41.8% per year) are forecast to grow faster than the German market (13.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GOV's revenue (17.4% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: GOV's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GOV's Return on Equity is forecast to be high in 3 years time (33.8%)
Next Steps
Past Performance
How has Insulet performed over the past 5 years?
43.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GOV has a large one-off loss of $17.2M impacting its September 30 2019 financial results.
Growing Profit Margin: GOV became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GOV has become profitable over the past 5 years, growing earnings by 43.8% per year.
Accelerating Growth: GOV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GOV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17%).
Return on Equity
High ROE: GOV's Return on Equity (11%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Insulet's financial position?
Financial Position Analysis
Short Term Liabilities: GOV's short term assets ($793.9M) exceed its short term liabilities ($113.3M).
Long Term Liabilities: GOV's short term assets ($793.9M) do not cover its long term liabilities ($1.0B).
Debt to Equity History and Analysis
Debt Level: GOV's debt to equity ratio (654.7%) is considered high.
Reducing Debt: GOV's debt to equity ratio has increased from 208.2% to 654.7% over the past 5 years.
Balance Sheet
Inventory Level: GOV has a high level of physical assets or inventory.
Debt Coverage by Assets: GOV's debt is not covered by short term assets (assets are 0.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GOV is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: GOV is profitable, therefore cash runway is not a concern.
Next Steps
Dividend
What is Insulet's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate GOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GOV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GOV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GOV's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.1yrs
Average management tenure
CEO
Shacey Petrovic (45yo)
1.1yrs
Tenure
US$3,664,805
Compensation
Ms. Shacey Petrovic serves as Director of Alydia Health, Inc. She is the President of Insulet Corporation since October, 2016 and its Director since September 10, 2018. She served as Chief Operating Office ...
CEO Compensation Analysis
Compensation vs Market: Shacey's total compensation ($USD3.66M) is about average for companies of similar size in the German market ($USD4.31M).
Compensation vs Earnings: Shacey's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.1yrs | US$3.66m | 0.093% $11.2m | |
| Executive VP & COO | 1.1yrs | US$2.62m | 0.041% $5.0m | |
| Executive VP & Chief Commercial Officer | 2.8yrs | US$1.69m | 0.0080% $966.7k | |
| 0.9yrs | US$1.43m | 0.084% $10.1m | ||
| Executive VP | 0.9yrs | no data | no data | |
| VP, Chief Accounting Officer & Controller | 0.8yrs | no data | 0.00028% $33.8k | |
| Vice President of Investor Relations & Corporate Communications | 5.1yrs | no data | no data | |
| Senior Vice President of Quality and Regulatory Affairs & Compliance | 3yrs | US$1.54m | 0.027% $3.3m | |
| Senior VP | 0.9yrs | no data | 0.00035% $42.3k | |
| Senior Vice President of Sales & Customer Care | 5.1yrs | no data | no data |
1.1yrs
Average Tenure
49yo
Average Age
Experienced Management: GOV's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.1yrs | US$3.66m | 0.093% $11.2m | |
| Independent Director | 11.3yrs | US$254.33k | 0.043% $5.2m | |
| Independent Chairman | 1.1yrs | US$252.73k | 0.034% $4.1m | |
| Chairman of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Educator Advisory Board | 0yrs | no data | no data | |
| Member of Educator Advisory Board | 0yrs | no data | no data | |
| Member of Educator Advisory Board | 0yrs | no data | no data | |
| Independent Director | 4yrs | US$270.12k | 0.010% $1.2m | |
| Lead Independent Director | 3.5yrs | US$299.89k | 0.033% $3.9m |
3.5yrs
Average Tenure
54yo
Average Age
Experienced Board: GOV's board of directors are considered experienced (3.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Insulet Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Insulet Corporation
- Ticker: GOV
- Exchange: DB
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$13.125b
- Listing Market Cap: US$12.083b
- Shares outstanding: 61.82m
- Website: https://www.insulet.com
Number of Employees
Location
- Insulet Corporation
- 100 Nagog Park
- Acton
- Massachusetts
- 1720
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PODD | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 2007 |
| GOV | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2007 |
| GOV | BRSE (Berne Stock Exchange) | Yes | Common Stock | CH | CHF | May 2007 |
Biography
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, the United Kingdom, the Netherlands, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/22 21:47 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.